Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 778

1.

Clinical utility of different lipid measures for prediction of coronary heart disease in men and women.

Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, Pencina MJ, Schoonmaker C, Wilson PW, D'Agostino RB, Vasan RS.

JAMA. 2007 Aug 15;298(7):776-85.

PMID:
17699011
2.

Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population.

Sierra-Johnson J, Fisher RM, Romero-Corral A, Somers VK, Lopez-Jimenez F, Ohrvik J, Walldius G, Hellenius ML, Hamsten A.

Eur Heart J. 2009 Mar;30(6):710-7. doi: 10.1093/eurheartj/ehn347. Epub 2008 Aug 1.

3.

Cholesterol and other lipids predict coronary heart disease and ischaemic stroke in the elderly, but only in those below 70 years.

Simons LA, Simons J, Friedlander Y, McCallum J.

Atherosclerosis. 2001 Nov;159(1):201-8.

PMID:
11689222
4.

Major lipids, apolipoproteins, and risk of vascular disease.

Emerging Risk Factors Collaboration., Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J.

JAMA. 2009 Nov 11;302(18):1993-2000. doi: 10.1001/jama.2009.1619.

5.

Non-HDL cholesterol vs. apo B for risk of coronary heart disease in healthy individuals: the EPIC-Norfolk prospective population study.

Sondermeijer BM, Rana JS, Arsenault BJ, Shah PK, Kastelein JJ, Wareham NJ, Boekholdt SM, Khaw KT.

Eur J Clin Invest. 2013 Oct;43(10):1009-15. doi: 10.1111/eci.12129. Epub 2013 Jul 17.

PMID:
23859101
6.

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr.

JAMA. 1998 May 27;279(20):1615-22.

PMID:
9613910
7.

Do lipids and apolipoproteins predict coronary heart disease under statin and fibrate therapy in the primary prevention setting in community-dwelling elderly subjects? The 3C Study.

Straczek C, Tafflet M, Barberger-Gateau P, Bertrand M, Dupuy AM, Ducimetière P, Empana JP.

Atherosclerosis. 2011 Feb;214(2):426-31. doi: 10.1016/j.atherosclerosis.2010.10.040. Epub 2010 Nov 3.

PMID:
21129746
8.

Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study.

Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W; Atherosclerosis Risk in Communities Study Group..

Circulation. 2001 Sep 4;104(10):1108-13.

9.

Apolipoprotein-B, low-density lipoprotein cholesterol, and the long-term risk of coronary heart disease in men.

St-Pierre AC, Cantin B, Dagenais GR, Després JP, Lamarche B.

Am J Cardiol. 2006 Apr 1;97(7):997-1001. Epub 2006 Feb 13.

PMID:
16563904
10.

Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk.

van der Steeg WA, Boekholdt SM, Stein EA, El-Harchaoui K, Stroes ES, Sandhu MS, Wareham NJ, Jukema JW, Luben R, Zwinderman AH, Kastelein JJ, Khaw KT.

Ann Intern Med. 2007 May 1;146(9):640-8.

PMID:
17470832
11.

Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men.

Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB.

Circulation. 2005 Nov 29;112(22):3375-83.

12.
13.

Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?

Simes RJ, Marschner IC, Hunt D, Colquhoun D, Sullivan D, Stewart RA, Hague W, Keech A, Thompson P, White H, Shaw J, Tonkin A; LIPID Study Investigators..

Circulation. 2002 Mar 12;105(10):1162-9.

14.
15.

Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.

Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, Deedwania P, Olsson AG, Boekholdt SM, Demicco DA, Szarek M, LaRosa JC, Pedersen TR, Grundy SM; TNT Study Group.; IDEAL Study Group..

Circulation. 2008 Jun 10;117(23):3002-9. doi: 10.1161/CIRCULATIONAHA.107.713438. Epub 2008 Jun 2.

16.

[Serum apolipoprotein B is superior to LDL-cholesterol level in predicting incident coronary disease among Turks].

Onat A, Ozhan H, Can G, Hergenç G, Karabulut A, Albayrak S.

Anadolu Kardiyol Derg. 2007 Jun;7(2):128-33. Turkish.

17.

Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.

Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E.

Arterioscler Thromb Vasc Biol. 2009 Mar;29(3):424-30. doi: 10.1161/ATVBAHA.108.181735. Epub 2009 Jan 2.

18.

Utility of non-high-density lipoprotein cholesterol versus other lipoprotein measures in detecting subclinical atherosclerosis in young adults (The Bogalusa Heart Study).

Frontini MG, Srinivasan SR, Xu JH, Tang R, Bond MG, Berenson G.

Am J Cardiol. 2007 Jul 1;100(1):64-8. Epub 2007 May 11.

PMID:
17599442
19.

The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women.

Everett BM, Kurth T, Buring JE, Ridker PM.

J Am Coll Cardiol. 2006 Dec 5;48(11):2235-42. Epub 2006 Nov 13.

20.

Efficacy of cholesterol levels and ratios in predicting future coronary heart disease in a Chinese population.

Wang TD, Chen WJ, Chien KL, Seh-Yi Su SS, Hsu HC, Chen MF, Liau CS, Lee YT.

Am J Cardiol. 2001 Oct 1;88(7):737-43.

PMID:
11589839

Supplemental Content

Support Center